Literature DB >> 28213789

A Novel Prognostic Scoring System Based on Preoperative Sarcopenia Predicts the Long-Term Outcome for Patients After R0 Resection for Gastric Cancer: Experiences of a High-Volume Center.

Zhi-Fang Zheng1, Jun Lu1, Chao-Hui Zheng1, Ping Li1, Jian-Wei Xie1, Jia-Bin Wang1, Jian-Xian Lin1, Qi-Yue Chen1, Mi Lin1, Chang-Ming Huang2.   

Abstract

BACKGROUND: The relationship between sarcopenia and prognosis of gastric cancer (GC) is unclear. This study aimed to develop a prognostic scoring system combining sarcopenia with preoperative clinical parameters for patients with GC to predict 3-year overall survival (OS) and 3-year recurrence-free survival (RFS).
METHODS: In this study, 924 patients with GC who underwent radical gastrectomy were retrospectively analyzed. The data were divided into a training set and a validation set. Sarcopenia was diagnosed by the cutoff value of the skeletal muscle index (SMI) obtained by X-tile software. The study used COX regression to identify preoperative risk factors associated with 3-year OS and RFS.
RESULTS: In the training set, 103 patients (14.8%) were sarcopenic based on the cutoff value of the SMI (32.5 cm2/m2 for men and 28.6 cm2/m2 for women). Multivariate analysis showed the following preoperative risk factors for the training set: sarcopenia and preoperative T (cT) and N (cN) stages. A prognostic scoring system was developed based on these findings. The 3-year OS rates were 89% for the low-risk patients, 77.9% for the intermediate-risk patients, and 54.8% for the high-risk patients (P < 0.001), and the 3-year RFS rates were respectively 86.9, 75.3 and 49.3% (P < 0.001). The area under the receiver operating characteristic curves were 0.708 for the 3-year OS rates and 0.713 for the 3-year RFS rates. The observed and predicted incidence rates for 3-year OS and RFS in the validation set did not differ significantly.
CONCLUSIONS: The prognostic scoring system combining sarcopenia with the cT and cN system can accurately predict 3-year OS and RFS rates after radical gastrectomy for GC.

Entities:  

Mesh:

Year:  2017        PMID: 28213789     DOI: 10.1245/s10434-017-5813-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  21 in total

1.  Reappraise role of No. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: a pooled analysis of 4 prospective trial.

Authors:  Qing Zhong; Qi-Yue Chen; Yan-Chang Xu; Gang Zhao; Li-Sheng Cai; Guo-Xin Li; Ze-Kuan Xu; Su Yan; Zu-Guang Wu; Fang-Qin Xue; Yi-Hong Sun; Dong-Po Xu; Wen-Bin Zhang; Jin Wan; Pei-Wu Yu; Jian-Kun Hu; Xiang-Qian Su; Jia-Fu Ji; Zi-Yu Li; Jun You; Yong Li; Lin Fan; Chao-Hui Zheng; Jian-Wei Xie; Ping Li; Chang-Ming Huang
Journal:  Gastric Cancer       Date:  2020-07-26       Impact factor: 7.370

2.  Predictive Value of Preoperative Sarcopenia in Patients with Gastric Cancer: a Meta-analysis and Systematic Review.

Authors:  Zhengdao Yang; Xin Zhou; Bin Ma; Yanan Xing; Xue Jiang; Zhenning Wang
Journal:  J Gastrointest Surg       Date:  2018-07-09       Impact factor: 3.452

3.  Prognostic Value and Association of Sarcopenia and Systemic Inflammation for Patients with Gastric Cancer Following Radical Gastrectomy.

Authors:  Jian-Xian Lin; Jun-Peng Lin; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ruhong Tu; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  Oncologist       Date:  2019-03-25

4.  Impact of loss of skeletal muscle mass within 6-12 months after gastrectomy and S1 adjuvant chemotherapy on the survival prognosis of elderly patients with gastric cancer.

Authors:  Shiro Fujihata; Shinichi Sakuramoto; Yosuke Morimoto; Kazuaki Matsui; Keiji Nishibeppu; Gen Ebara; Shohei Fujita; Shuichiro Oya; Hirofumi Sugita; Seigi Lee; Yutaka Miyawaki; Hiroshi Sato; Shuji Takiguchi; Keishi Yamashita
Journal:  Surg Today       Date:  2022-04-08       Impact factor: 2.540

5.  Effect of progressive sarcopenia during postoperative 6 months on long-term prognosis of completely resected lung cancer.

Authors:  Masashi Nagata; Hiroyuki Ito; Tomoyuki Yokose; Akihiro Tokushige; Shinichiro Ueda; Haruhiko Nakayama
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

6.  Strong impact of sarcopenia as a risk factor of survival in resected gastric cancer patients: first Italian report of a Bicentric study.

Authors:  A A Ricciardolo; N De Ruvo; F Serra; F Prampolini; L Solaini; S Battisti; G Missori; S Fenocchi; E G Rossi; L Sorrentino; M Salati; A Spallanzani; N Cautero; A Pecchi; G Ercolani; R Gelmini
Journal:  Updates Surg       Date:  2021-10-26

7.  Multivisceral Resection for Locally Advanced Gastric Cancer.

Authors:  John G Aversa; Laurence P Diggs; Brendan L Hagerty; Dana A Dominguez; Philip H G Ituarte; Jonathan M Hernandez; Jeremy L Davis; Andrew M Blakely
Journal:  J Gastrointest Surg       Date:  2020-07-23       Impact factor: 3.267

8.  Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer.

Authors:  Jong Soo Lee; Young Saing Kim; Eun Young Kim; Wook Jin
Journal:  PLoS One       Date:  2018-08-20       Impact factor: 3.240

9.  Preoperative skeletal muscle index vs the controlling nutritional status score: Which is a better objective predictor of long-term survival for gastric cancer patients after radical gastrectomy?

Authors:  Zhi-Fang Zheng; Jun Lu; Jian-Wei Xie; Jia-Bin Wang; Jian-Xian Lin; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Chao-Hui Zheng; Chang-Ming Huang; Ping Li
Journal:  Cancer Med       Date:  2018-06-28       Impact factor: 4.452

10.  Comparison of skeletal muscle index-based formula and body surface area-based formula for calculating standard liver volume.

Authors:  Geunhyeok Yang; Shin Hwang; Gi-Won Song; Dong-Hwan Jung
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.